Diag Capital Management, LP
Reported holdings as of Q4 2018, from 1 quarterly filings.
This filer last reported in Q4 2018; the most recent quarter on file across all filers is Q2 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.
Holdings
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| BAXTER INTL INC | BAX | $5.7M | 85,933 | - | new | FIRST | |
| ATHENEX INC | ATNX | $5.4M | 429,046 | - | new | FIRST | |
| ZIMMER BIOMET HOLDINGS INC | ZBH | $4.9M | 47,684 | - | new | FIRST | |
| ABBVIE INC | ABBV | $4.6M | 50,420 | - | new | FIRST | |
| INCYTE CORP | INCY | $4.6M | 72,196 | - | new | FIRST | |
| QUANTERIX CORP | QTRX | $4.1M | 223,949 | - | new | FIRST | |
| CELGENE CORP | CELG | $4.0M | 63,159 | - | new | FIRST | |
| AMGEN INC | AMGN | $3.9M | 20,110 | - | new | FIRST | |
| MEDTRONIC PLC | MDT | $3.3M | 36,180 | - | new | FIRST | |
| QUOTIENT LTD | QTNT | $3.2M | 526,932 | - | new | FIRST | |
| PCRX 3.25 2/19 | $3.2M | 74,502 | - | new | DEBT | ||
| TAKEDA PHARMACEUTICAL CO LTD | TAK | $3.0M | 177,260 | - | new | FIRST | |
| ABBOTT LABORATORIES | ABT | $2.8M | 38,585 | - | new | FIRST | |
| ZAI LAB LTD | ZLAB | $2.8M | 120,092 | - | new | FIRST | |
| MYLAN N V | MYL | $2.7M | 99,410 | - | new | FIRST | |
| POLARITYTE INC | PTE | $2.5M | 182,833 | - | new | FIRST | |
| VIEWRAY INC | VRAYQ | $2.4M | 397,375 | - | new | FIRST | |
| REGENERON PHARMACEUTICALS | REGN | $2.2M | 5,792 | - | new | FIRST | |
| TEVA PHARMACEUTICAL INDS LTD | TEVA | $2.2M | 139,531 | - | new | FIRST | |
| AKORN INC | AKRXQ | $2.1M | 634,046 | - | new | FIRST | |
| HAEMONETICS CORP MASS | HAE | $2.1M | 21,220 | - | new | FIRST | |
| ARGENX SE | ARGX | $1.6M | 16,712 | - | new | FIRST | |
| BIOHAVEN PHARMACTL HLDG CO L | BHVNXXXX | $1.4M | 38,319 | - | new | FIRST | |
| MERIT MED SYS INC | MMSI | $1.4M | 25,092 | - | new | FIRST | |
| SANOFI SA | SNY | $1.3M | 30,240 | - | new | FIRST | |
| GW PHARMACEUTICALS PLC | GWPH | $1.3M | 13,460 | - | new | FIRST | |
| LIVANOVA PLC | LIVN | $1.1M | 11,974 | - | new | FIRST | |
| MOLECULAR TEMPLATES INC | MTEM | $985.0K | 243,839 | - | new | FIRST | |
| FOAMIX PHARMACEUTICALS LTD | FOMX | $960.0K | 146,432 | - | new | FIRST | |
| VERRICA PHARMACEUTICALS INC | VRCA | $937.0K | 114,947 | - | new | FIRST | |
| NEUROCRINE BIOSCIENCES INC | NBIX | $876.0K | 12,266 | - | new | FIRST | |
| DENTSPLY SIRONA INC | XRAY | $757.0K | 20,347 | - | new | FIRST | |
| AXONICS INC | AXNX | $702.0K | 46,485 | - | new | FIRST | |
| ARYA SCIENCES ACQUISITION CO | ARYAU | $522.0K | 50,500 | - | new | FIRST | |
| ADMA BIOLOGICS INC | ADMA | $435.0K | 182,100 | - | new | FIRST | |
| MADRIGAL PHARMACEUTICALS INC | MDGL | $326.0K | 2,890 | - | new | FIRST | |
| ARVINAS INC | ARVN | $311.0K | 24,210 | - | new | FIRST | |
| NOVAVAX INC | $286.0K | 155,320 | - | new | DEBT | ||
| NEOS THERAPEUTICS INC | NEOS | $278.0K | 168,642 | - | new | FIRST | |
| ANAPTYSBIO INC | ANAB | $95.0K | 1,493 | - | new | FIRST |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Biotech & Pharma | $36.0M | 41.2% |
| Medical Devices | $19.3M | 22.0% |
| Not classified | $32.1M | 36.8% |
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q4 2018 | $87.4M | 40 | 0 | 0 | 0 | 0 | 50.2% | 45 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.